-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In Israel, 2020 December 20 start nationwide new crown pneumonia mRNA vaccine (BNT162b2) vaccination, as of May 5, 2021, 58.
2% of the Israeli population vaccinated with at least one vaccine, 54.
6% had completed 2 vaccinations
.
On May 27, 2021, the Centers for Disease Control and Prevention (CDC) issued a statement stating that the BNT162b2 vaccine and mRNA-1273 vaccine may be associated with the risk of myocarditis
New coronary pneumonia prevention Recently, researchers have systematically studied the risk of myocarditis in vaccinating the new coronary pneumonia mRNA vaccine
The researchers searched Israel's largest health care organization (HCO)-Clalit health service organization database data, looking for patients with myocarditis diagnosed after receiving at least one dose of the BNT162b2 vaccine.
The diagnosis of myocarditis was made by a professional doctor
.
The clinical manifestations, course and results are extracted from the electronic health records of the patients
diagnosis
The HCO database contains data on 2.
5 million vaccinated populations over 16 years old, and 54 of them have been diagnosed with myocarditis
.
After vaccination with at least one dose of the vaccine, there were 2.
After vaccination with at least one dose of the vaccine, there were 2.
Cumulative myocarditis events 42 days after vaccination
Cumulative myocarditis events 42 days after vaccination Cumulative myocarditis events 42 days after vaccinationThe study found that in people who received at least one dose of BNT162b2 mRNA vaccine, the incidence of myocarditis was 2.
13 cases per 100,000 people.
Among them, people aged 16-29 had the highest risk, and most cases of myositis were mild or moderate
.
13 cases per 100,000 people.
Among them, people aged 16-29 had the highest risk, and most cases of myositis were mild or moderate
.
In people who received at least one dose of BNT162b2 mRNA vaccine, the incidence of myocarditis was 2.
Guy Witberg et al.
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
Leave a message here